cyrilzakka/clinical-trials huggingface dataset:
Progesterone Supplementation in Frozen Embryo Transfer Cycles

Recurrent implantation failure (RIF) occurs after women undergo in vitro fertilization and have multiple embryos transferred but no resulting pregnancies. RIF is a very challenging clinical entity for the reproductive physician and the patient. In fact, there is not even an agreed upon definition in the medical community. Many potential causes have been investigated over the past several years but no clear answer has emerged. Interest has recently turned to the endometrium, or the lining of the uterus. Studies have shown that the genes that are turned on in the endometrium vary based on how long this tissue has been exposed to progesterone, an important hormone that prepares the uterine lining for implantation of the growing embryo. In some women, it seems that they require longer periods of progesterone exposure to reach the same state of readiness. We hypothesize that an even larger proportion of women in RIF population will require longer treatments with progesterone.

In this study, we will randomize women with RIF who are about to undergo a frozen embryo transfer to one of two groups. The first group will have their embryo transfer done on the standard sixth day of progesterone treatment. The other group will have their transfer done on the seventh day of progesterone. We will be comparing the clinical pregnancy rate of the two groups as well as the live birth rate and miscarriage rate. We expect that extending the progesterone treatment by one day will increase the pregnancy rate of women with RIF.


Eligibility Criteria:
Inclusion Criteria:

* Patient at Mount Sinai Fertility who wants to undertake a frozen embryo transfer
* History of recurrent implantation failure, defined as no pregnancy after three or more embryo transfers of four or more good quality blastocysts

Exclusion Criteria:

* Previous testing with Endometrial Receptivity Assay (ERA)
* Unable understand/communicate in English
A Study of ISIS 2922 in the Treatment of Advanced Cytomegalovirus Retinitis

The purpose of this study is to compare the safety and effectiveness of two dosage schedules for ISIS 2922 in the treatment of advanced cytomegalovirus (CMV) retinitis

This is a multicenter, prospective, randomized, open-label study comparing 2 dosage schedules of ISIS 2922.

Eligibility Criteria:
Inclusion Criteria

Concurrent Medication:

Allowed:

* Oral ganciclovir.
* Leukocyte growth factors (GM-CSF and G-CSF) for patients with febrile neutropenia.

Patients must have:

* Documented AIDS.
* Clinical diagnosis of advanced CMV retinitis in 1 or both eyes.
* \>= 2 previous induction courses with anti-CMV retinitis therapy licensed by a regulatory agency.
* \> 25% retinal involvement with CMV retinitis.
* Baseline CMV retinitis lesions which have leading edges \> 1000 micrograms from the macula or optic disk.

Prior Medication:

Required:

* \>= 2 previous induction courses with anti-CMV retinitis therapy licensed by a regulatory agency.

Allowed:

* All anti-CMV therapies other than ganciclovir must be discontinued no less than 2 days prior to entry.

Exclusion Criteria

Co-existing Condition:

Patients with the following symptoms and conditions are excluded:

* External ocular infection in the eye to be treated.
* Other herpetic infections of the retina, toxoplasma, retinochoroiditis, or other disease of the fundus that would preclude assessment of CMV retinitis in the eye to be treated.
* Ocular conditions that will obstruct visualization of the posterior ocular structures on the eye to be treated.
* Retinal detachment in the eye to be treated.
* Ganciclovir implant in the eye to be treated.
* Known or suspected allergy to phosphorothioate oligonucleotides or intolerance of ISIS 2922.
* Silicone oil in the eye to be treated.
* Pseudoretinitis pigmentosa.
* Syphilis.

Patients with the following prior conditions are excluded:

* History of surgery to correct retinal detachment in the eye to be treated.
* History of syphilis.

  1. Systemic anti-CMV therapies other than oral ganciclovir.
* Mellaril, Stelazine, chlorpromazine and clofazimine.
* Combination use of ethambutol and fluconazole.
* Investigational medications and/or procedures for the treatment of CMV retinitis in the eye to be treated.
* Ganciclovir implant delivery device in the eye to be treated.
* Ganciclovir other than oral.
* Foscarnet.
Prospective Registry on User Experience With The Mapping System For Ablation Procedures

This is an observational, prospective, non-randomized, multicenter, post approval study being conducted in the United States, Europe and Asia-Pacific Regions.

The TRUE HD Study is aimed at collecting real-world data on the use of the Rhythmia mapping system and the IntellaMap Orion mapping catheter in patients indicated for ablation procedure with use of a 3D Mapping system.

The study will collect specific information on management of ablation procedures with the commercial system including but not limited to acute procedural success, type and proportion of arrhythmias mapped/treated, and how mapping system is used overall. Usage data may be used for the planning of future clinical trials.

Eligibility Criteria:
Inclusion Criteria:

* Subjects who are eligible for an ablation procedure with the Rhythmia 3D mapping system and IntellaMap Orion mapping catheter according to current international and local guidelines (and future revisions) and per physician discretion;
* Subjects who are willing and capable of providing informed consent;
* Subjects who are willing and capable of participating in all testing associated with this clinical investigation at an approved clinical investigational center;
* Subjects whose age is 20 years or above, or of legal age to give informed consent specific to state and national law.

Exclusion Criteria:

* Subjects requiring de novo ablation of atrial fibrillation;
* Subjects who are currently enrolled in another investigational study or registry that would directly interfere with the current study, except when the subject is participating in a mandatory governmental registry, or a purely observational registry with no associated treatments; each instance must be brought to the attention of the sponsor to determine eligibility\*;
* The subject is unable or not willing to complete follow-up visits and examination for the duration of the study;
* Subjects who have undergone a previous cardiac ablation within 30 days prior to enrollment;
* Unrecovered/unresolved Adverse Events from any previous invasive procedure;
* Women of childbearing potential who are, or plan to become, pregnant during the time of the study (method of assessment upon physician's discretion).
Anti-Mullerian Hormone Changes After Laparoscopic Ovarian Cystectomy for Endometrioma Compared With the Non-ovarian Conditions

This aim of the study is to evaluate the impact of endometrioma and laparoscopic cystectomy on ovarian reserve as measured by serum antimullerian hormone and to study the different effects of levels of serum antimullerian hormone between laparoscopic cystectomy and the non-ovarian pelvic surgery.


Eligibility Criteria:
Inclusion Criteria:

* • Participants must be between the ages of 18 - 45 during enter the study .

  * Every participants have to completely understand the process of this study and have written informed consent .
  * Having regular menstrual cycles (21-35 days) at the time of operation
  * no evidence of any other endocrine disorders such as diabetes mellitus, thyroid dysfunction, hyperprolactinemia, congenital adrenal hyperplasia, Cushing's syndrome, or adrenal insufficiency.
  * undergo laparoscopic ovarian cystectomy or laparoscopic non- ovarian pelvic surgery for benign pelvic disease
  * No previous history of adnexal surgery
  * No any suspicious findings of malignant ovarian diseases
  * Never taking any medication such as oral pill and hormonal drugs within 3 months before the enrollment.
  * pathological diagnosis of excised ovarian tissue confirm as endometriotic cyst in study group and other benign pelvic disease in control group

Exclusion Criteria:

* polycystic ovarian syndrome according to the Rotterdam criteria

  * pathological report as the malignant diseases
  * have operation conversion to open-laparotomy
Prevalence and Incidence of Multiple Revisions Following Knee Arthroplasty in Denmark 1998-2021: A Nationwide Population-based Study

The purpose of this study is to investigate the incidence and prevalence rates of multiply revised knee arthroplasty patients in Denmark from 1998-2021.


Eligibility Criteria:
Inclusion Criteria:

* Danish Resident
* between 18-99 years of age
* must have had primary knee arthroplasty procedure performed in Denmark between 1998-2021

Exclusion Criteria:

* Missing key variables (patient ID, date of surgery, procedure-code, laterality of procedure)
* Duplicates
* Non-relevant procedures
The "Light for the Brain" Study

Cognitive impairment (such as memory problems) due to cancer and its treatment can interfere with quality of life and can linger long after treatment has ended, yet research examining cognitive rehabilitation approaches has produced limited clinical benefit. The proposed study will provide information about systematic light exposure for the treatment of cognitive impairment in hematopoietic stem cell transplant (HSCT) survivors and will investigate how it works. This study would facilitate the development of this potential treatment, giving health care providers and cancer survivors a much-needed tool to help with cancer-related cognitive impairment.


Eligibility Criteria:
Inclusion Criteria:

1. Have a history of HSCT,
2. 1 to 5 years post-HSCT,
3. Relapse-free since most recent HSCT,
4. Age 21 or older,
5. English language proficient
6. Able to provide informed consent
7. Endorse subjective cognitive impairment.

Exclusion Criteria:

1. Diagnosed or suspected neurological, psychiatric (including bipolar disorder or mania), or medical condition that might impair cognitive functioning (other than those caused by the cancer or its treatment),
2. Visual, hearing, or physical impairment sufficient to interfere with cognitive testing or participation,
3. Have a history of whole brain irradiation or surgery,
4. Active diagnosis of autoimmune and/or inflammatory disorder or disorders that may influence immune processes,
5. Chronic use of oral steroid medication,
6. History of systematic light exposure treatment,
7. Diagnosed sleep apnea or narcolepsy,
8. Use of photosensitizing medications,
9. Plan to travel across meridians during the study,
10. Work night, early morning, or swing shifts,
11. Adults unable to consent, individuals who are not yet adults, pregnant women and prisoners will be excluded from the study.
Cervical Spinal Manipulation and Visteral Osteopathy for Mechanical Neck Pain

This study compares two treatment techniques, cervical spinal manipulation (CSM) and visceral osteopathy (VO), in patients with mechanical neck pain (MNP). The aim of the study was to evaluate the effects of these treatments on pain levels, neck mobility, and muscle strength in both the neck and upper extremities.

The purpose of this study is to compare the acute effects of cervical spinal manipulation (CSM) treatment and visceral osteopathy (VO) techniques on pain, cervical range of motion (ROM), muscle strength, and grip strength in individuals with mechanical neck pain (MNP).

The study is going to include a total of 30 subjects aged 18-60 diagnosed with MNP. The subjects are randomly divided into two groups. The CSM group received high-velocity, low-amplitude (HVLA) spinal manipulation, while the other group underwent VO techniques. Each treatment technique is going to be applied in only one session. Pain intensity is assessed using the Visual Analog Scale (VAS). Cervical ROM and the craniovertebral angle (CVA) are evaluated using a goniometer. Neck and elbow muscle strength are measured with a hand-held dynamometer, and grip strength is assessed using a hand-grip dynamometer.

Eligibility Criteria:
Inclusion Criteria:

* Participants is included if they had neck pain present for at least one week, reduced cervical ROM, a manual muscle test score of 4 or higher for the neck muscles, and no neurological pain in the neck.

Exclusion Criteria:

* Exclusion criteria included individuals with rheumatic diseases, a history of spinal surgery, neck fractures, tumors in the neck region, vertebrobasilar artery insufficiency, blood clotting disorders, or inadequate mental capacity.
Safety and Reactogenicity of Bioconjugate Vaccine to Prevent Shigella

Healthy volunteers will receive a 2-dose vaccination with Shigella dysenteriae candidate vaccine spaced 8 weeks apart. The objective is to demonstrate the safety and reactogenicity of the Shigella dysenteriae bioconjugate vaccine (GVXN SD133) alone or in combination with an adjuvant (Aluminium Hydroxide). The safety and reactogenicity of the GVXN SD133 vaccine will be also evaluated at two different concentrations of antigen, Shigella polysaccharide O1. Blood samples will be collected at intervals to examine systemic vaccine antigen-specific immune responses.


Eligibility Criteria:
Inclusion Criteria:

* Subjects of both sexes, aged between 18 and 50 years.
* Subjects who have undergone a detailed medical history, clinical checkup and are in good health.
* Subjects who have understood the purpose of the study and have freely signed the informed consent.
* Subjects who consent with repeated blood samples taking.
* Subjects who will be available to perform the follow-up visits, are reachable by telephone, and are able to complete the diary cards throughout the study duration.
* For female volunteers, a negative pregnancy test and an adequate contraception throughout the study duration.

Exclusion Criteria:

* Known history of recent contact Shigella infection or long-term residence in a Shigella endemic region (Central America, Africa, and India).
* Known history of hypersensitivity to any component of the vaccine (EPA; Aluminium Hydroxide).
* Subjects with compromised immune system.
* Family history of congenital or hereditary immunodeficiency.
* Chronic administration of an immunosuppressive treatment or other immune-modifying drugs within six months prior to the first vaccine dose.
* Subjects that received any other vaccine during the 1 month preceding the 1st injection and may receive before the 2nd injection. If the subject needs to be vaccinated during this period, he/she will be withdrawn from the study.
* Subjects suffering of a disease at the time of enrolment. 'Disease' is defined as the presence of a mild or severe illness with or without fever.
* Acute or chronic, clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined by physical examination or laboratory screening tests.
* Any laboratory data collected during the screening phase found to be outside the normal range defined by the laboratory.
* Positive test for HIV, and evidence of HBV or HCV.
* Pregnant or breast-feeding women.
* History of alcohol, drug or psychotropic drug abuse (which interferes with a normal lifestyle) during the previous year.
* Subjects for which follow-up is compromised due to socio-cultural, geographic or psychological reasons.
* Any other significant finding that in the opinion of the Investigator that would increase the risk of having an adverse outcome from participating in the study.
* Subjects that are participating or have participated in another clinical trial in the last 6 months.
Pulmonary Embolism Short-term Clinical Outcomes Registry

The overall goal of this clinical research study is to prospectively assess primary outcomes related to pulmonary embolism (PE) that occur immediately (within 5 days) and within 30 days. The secondary goal is to compare validated prediction models and a modified European Society of Cardiology (ESC) approach that is primarily right ventricle dysfunction (RVD) driven with clinical risk assessment being secondary, and with primary outcomes of clinical deterioration within 5 days.

The investigators wish to develop the Pulmonary Embolism Short-term Clinical Outcomes Registry (PE-SCOR). The investigators also wish to determine the incidence of death and circulatory and respiratory deterioration, and administration of reperfusion therapy within 5 days in PE patients. The study will also evaluate the sensitivity, specificity and positive and negative predictive values of each RVD assessment option. The investigators will also derive a prediction model for PE patients for the primary outcome within five days. Finally, investigators will determine the functional outcomes of PE patients 30 days after PE.

Eligibility Criteria:
Inclusion Criteria:

* Patients 18 years or older with image confirmed acute pulmonary embolism diagnosed within 12 hours of ED presentation will be eligible for enrollment.

Exclusion Criteria:

* Patients who refuse consent for 30-day clinical contact and follow-up.
Multiple Dose-escalation Study of AMA0076 in Patients With Ocular Hypertension or Primary Open-angle Glaucoma

The objective of this dose-escalation study is to evaluate the safety, tolerability and efficacy of AMA0076 in reduction of intraocular pressure in subjects with ocular hypertension or primary open-angle glaucoma.


Eligibility Criteria:
Inclusion Criteria include:

1. Adults 30-85 years of age
2. Diagnosis of either ocular hypertension or primary open-angle glaucoma in both eyes
3. Not receiving medication for IOP, or able to stop such medication for a washout period and the duration of the study without significant risk of adverse consequences related to glaucomatous disease
4. Elevated IOP (≥ 24 and ≤ 34 mm Hg at 8 AM and ≥ 21 and ≤ 34 mm Hg at 10 AM on Screening Two visit and Baseline visit in one or both eyes off treatment

Exclusion Criteria include:

1. Uncontrolled intraocular hypertension defined as \>34 mm Hg at either of the screening/baseline visits (after a washout phase in those subjects who were currently receiving ocular hypotensive therapy).
2. Receiving more than one medication for IOP at time of screening.
3. Central corneal thickness of less than 500 µm or greater than 620 µm.
4. BCVA worse than 20/200 in either eye
5. Significant visual field loss (ie, mean deviation \> 10 db or field loss within 10 degrees of fixation), a new field defect, or progression of an existing field defect in either eye during the year preceding the study.
6. Acute angle-closure glaucoma or appositional or very narrow anterior chamber angle in either eye.
Using Online Videos to Supplement Emergency Department Discharge Instructions

This project will evaluate the effectiveness of 38 videos of discharge instructions for patients seen in, and discharged from, the emergency department (ED). The investigators will (1) assess how many ED patients chose view the website, and (2) interview patients who viewed a video, as well as those who didn't view a video (and therefore received standard care), to determine whether patients who viewed a video understood their diagnoses and discharge instructions better.


Eligibility Criteria:
Inclusion Criteria:

* Age \> 16, or \< 16 and accompanied by a legal guardian
* Has one of 38 ED discharge diagnoses
* Fluent in English, or caregiver fluent
* Has access to a computer, with internet access, in the next 4 days
* Has access to a telephone

Exclusion Criteria:

* Age \< 16 when unaccompanied by a legal guardian
* Decreased level of consciousness at ED discharge (eg palliative patient)
Photodynamic Therapy in Occult-Only Lesions (POOL)

Age related macular degeneration is the leading cause of blindness for people over 50 in the western world. Blood vessels which start to grow form a lesion in the back of the eye. Verteporfin may stabilize the disease, by closing the blood vessels. This study will assess the efficacy and safety of verteporfin in patients with occult only lesions.


Eligibility Criteria:
Inclusion Criteria:

* 50 years or older
* Must see better or equal to 34 letters (visual acuity)
* Choroidal neovascularization (CNV) lesion must be occult only

Exclusion Criteria:

* Evidence of classic CNV in the lesion
* Prior treatment of disease in study eye
* Have a history of moderate to severe hepatic impairment

Other protocol-defined exclusion criteria may apply.
Study on the Correlation Between Fat Soluble Vitamins and Non-alcoholic Fatty Liver Disease

Excessive or insufficient levels of vitamins in the body can affect health. With the prevalence of obesity and MetS, NAFLD has become the leading cause of chronic liver disease and abnormal liver biochemical indicators in health examinations in China. The current research results on serum vitamin A, D, and E levels in NAFLD patients are controversial. Therefore, this study mainly explores the correlation between serum FSV levels and NAFLD, providing reference for nutrition and clinical management of NAFLD patients.

This is a single center cross-sectional study. In this study, 4000 eligible patients will be recruited and demographic information and clinical data of all study subjects will be collected. According to the results of abdominal ultrasound, the patients were divided into NAFLD group and non NAFLD group. The levels of fat soluble vitamins in the two groups were compared to explore the correlation between different concentrations of fat soluble vitamin levels and the risk of NAFLD.

Eligibility Criteria:
Inclusion Criteria:

1. Age ≥ 18 years old, both male and female;
2. Voluntarily participate in this study and sign an informed consent form;
3. Diagnosed NAFLD through abdominal ultrasound;

Exclusion Criteria:

1. Acute and chronic infections, severe cardiovascular and cerebrovascular diseases, respiratory system diseases, urinary system diseases, rheumatic diseases, tumors, and pituitary dysfunction; Or have hepatitis B, hepatitis C virus, or acquired immunodeficiency syndrome;
2. Surgery was performed within 6 months, and blood donation, transfusion, or significant blood loss occurred within 4 months;
3. Have taken vitamin supplements within 2 weeks;
4. Women are in pregnancy, lactation, or within one year after childbirth;
5. Alcohol abuse (alcohol intake ≥ 140 g/week for males and ≥ 70 g/week for females)
6. The serum creatinine (SCr) exceeds twice the following abnormal values, with the standard of abnormal values being: male (20-59 years old)\>97 μ mol/L, male (60-79 years old)\>111 μ mol/L; Female (20-59 years old)\>73 μ mol/L, female (60-79 years old)\>81 μ mol/L.